It's great to have her and also that she listens to what will be new and what will be coming in the next years in ophthalmology.

Of course.

Yeah.

I think having, again, having a regulatory presence is extremely important.

It is very rare to have regulatory in the room together with physicians, with innovators, with investors.

So here at firsthand, how the thought process of regulatory is different.

for various disease endpoints and approval indications and so forth is extremely important for everyone.

And so, of course, what do you think? I mean, do you think the European Medicines Agency is developing? Are we seeing Europe as a good destination to begin trials, to have first to market? Or is that still a little bit away from your side of the pond?